Your browser doesn't support javascript.
loading
Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.
Rozylo, Jennifer; Mitchell, Keren; Nikoo, Mohammadali; Durante, S Elise; Barbic, Skye P; Lin, Daniel; Mathias, Steve; Azar, Pouya.
Afiliação
  • Rozylo J; University of British Columbia, Vancouver, BC, Canada.
  • Mitchell K; University of British Columbia, Vancouver, BC, Canada.
  • Nikoo M; Inner City Youth Program, Providence Health Care, Vancouver, BC, Canada.
  • Durante SE; Foundry, Providence Health Care, Vancouver, BC, Canada.
  • Barbic SP; St Paul's Hospital, Vancouver, BC, Canada.
  • Lin D; University of British Columbia, Vancouver, BC, Canada.
  • Mathias S; Addiction and Concurrent Disorders Group, Institute of Mental Health, University of British Columbia, Vancouver, BC, Canada.
  • Azar P; Inner City Youth Program, Providence Health Care, Vancouver, BC, Canada.
Addict Sci Clin Pract ; 15(1): 2, 2020 01 15.
Article em En | MEDLINE | ID: mdl-31941547
ABSTRACT

BACKGROUND:

The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. CASE PRESENTATION We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a buprenorphine/naloxone microdosing schedule, we initiated treatment of an individual's opioid use disorder. There was a successful buprenorphine/naloxone microdosing induction as the team reached a therapeutic dose of buprenorphine/naloxone. Including the induction period, the medication was used consistently for 4 weeks.

CONCLUSIONS:

A microdosing schedule can be used to induce a patient onto buprenorphine/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento de Substituição de Opiáceos / Combinação Buprenorfina e Naloxona / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento de Substituição de Opiáceos / Combinação Buprenorfina e Naloxona / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article